Browsing: Medication & Drugs

FDA Urges Healthcare Professionals to Report Adverse Reactions to Anesthesia

By 0

In a recent announcement, the Food and Drug Administration (FDA) has urged healthcare professionals to promptly report any adverse reactions linked to the use of anaesthesia. This directive comes in response to mounting concerns raised by healthcare practitioners regarding the efficacy of certain anaesthesia products. Particularly, those containing bupivacaine, a potent local anaesthetic, have drawn significant attention. The FDA’s stance aims to address these concerns and ensure patient safety in anaesthesia administration.

Biyaheng Kalusugan: Transformative Initiatives Against Substance Abuse in PH

By 0

In a concerted effort to combat the pervasive issue of substance abuse, the Department of Health (DOH) recently initiated the Biyaheng Kalusugan: Drug Abuse Prevention and Control (DAPC) Week. This transformative event, held in collaboration with a variety of stakeholders, seeks to mobilise communities, fostering awareness about the danger of substance abuse and advocating for healthier choices, community resilience, and robust support systems.

Not just weight loss – Semaglutide and Cardiovascular Benefits

By 0
With the emergence and increasing popularity of glucagon-like peptide 1 (GLP-1) agonists for the treatment of obesity in recent years, it might be worth investigating if these agents are able to reduce the cardiovascular risks associated with overweight and obesity, especially since they have been shown to reduce risk of major adverse cardiovascular events in patients with type 2 diabetes who are at high cardiovascular risk.

Log In or Register as a healthcare professional to read the full article.

Intravenous Iron In Ambulant Patients With Heart Failure – Do We See The Same Benefits?

By 0
Iron deficiency is present in 50% of the patients with heart failure and it is associated with worse symptoms and outcomes [1]. There have been a few studies analysing the benefit of intravenous (IV) ferric carboxymaltose in heart failure with iron deficiency. In the AFFIRM-AHF [2] trial, administration of IV ferric carboxymaltose reduced the risk of cardiovascular death and total hospitalisations for heart failure in patients hospitalized for acute heart failure.

Log In or Register as a healthcare professional to read the full article.